...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of women’s health >Effect of Flibanserin Treatment on Body Weight in Premenopausal and Postmenopausal Women with Hypoactive Sexual Desire Disorder: A Post Hoc Analysis
【24h】

Effect of Flibanserin Treatment on Body Weight in Premenopausal and Postmenopausal Women with Hypoactive Sexual Desire Disorder: A Post Hoc Analysis

机译：氟氯苯磺酸治疗对高血压性欲望障碍患者体重和绝经后妇女体重的影响：HOC分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Flibanserin, a 5-HT1A agonist and 5-HT2A antagonist, is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This post hoc analysis evaluated the effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with HSDD. Materials and Methods: This analysis included three 24-week, double-blind, placebo-controlled studies of flibanserin 100mg each bedtime (qhs) in premenopausal women, a similarly designed study in postmenopausal women, and a 52-week, open-label extension study in premenopausal women. Results: In a pooled analysis of premenopausal women, mean baseline body mass index (BMI) was 27.0kg/m(2) in the flibanserin group (n=1227) and 26.8kg/m(2) in the placebo group (n=1238). Among patients who completed 24 weeks of treatment, least squares (LS) mean weight change was -1.4kg in the flibanserin group (n=1010) and -0.1kg in the placebo group (n=1066; p 12 months (n=880) and >18 months (n=637) of exposure to flibanserin, mean weight change was -1.0 and -1.2kg, respectively; 25.4% and 26.9% of patients, respectively, experienced weight loss 5% from baseline, and 7.8% and 8.4%, respectively, experienced weight loss 10%. Conclusions: Women treated with flibanserin for HSDD may experience weight loss.
机译：背景：Flibanserin，5-HT1A激动剂和5-HT2A拮抗剂，用于治疗前进女性中获得的，广义的低血压性欲障碍（HSDD）。该后HOC分析评估了氟氯苯磺酸对患有HSDD患者和绝经后妇女体重的影响。材料和方法：该分析包括三个24周，双盲，安慰剂对照研究的氟哌猴100mg每睡觉妇女的每桶（QHS），在绝经后妇女的同样设计的研究中，以及52周，开放标签延伸在前进女性的研究。结果：在对前辈女性的汇总分析中，平均基线体重指数（BMI）在Plibanserin组（N = 1227）中为27.0kg / m（2），安慰剂组中26.8kg / m（2）（n = 1238）。在治疗24周的患者中，在安慰剂组（N = 1066; P 12个月（N = 880）中，最小二乘（LS）平均重量变化为-1.4kg。（n = 1066; p 12个月（n = 880） ）和> 18个月（n = 637）暴露于氟哌猴，平均重量变化分别为-1.0和-1.2kg; 25.4％和26.9％的患者，患者的体重减轻5％，7.8％和7.8％分别为8.4％，经历了体重减轻10％。结论：用氟氯磺斯汀对HSDD治疗的女性可能会遇到体重减轻。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号